NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Holder | Stake |
|---|---|
| Kishor M. Shah | 2.39% |
| Rimo Capital Fund Lp | 1.35% |
| Dheeraj Kumar Lohia | 1.24% |
| Document | Date |
|---|---|
| Annual report FY2026 LINCOLN PHARMACEUTICALS LIMITED – ANNUAL REPORT FY 2025-26 SUMMARY --- HEADLINE NUMBERS • Total Income FY26: ₹70,448.39 lakhs vs FY25 ₹64,570.72 la | 2026-09-05 |
| Quarterly results · Q1 FY27 LINCOLN PHARMACEUTICALS LTD - DOCUMENT SUMMARY HEADLINE NUMBERS • Q1 FY27 (Quarter ended June 30, 2026) - Consolidated Results: - Net Profit: Rs. | 2026-08-13 |
| Quarterly results · Q4 FY26 LINCOLN PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY Year Ended March 31, 2026 --- HEADLINE NUMBERS • Revenue from Operations (FY2026): ₹67,102.99 l | 2026-05-28 |
| Quarterly results | 2026-04-08 |
| Q3 FY26 earnings call LINCOLN PHARMACEUTICALS LIMITED – SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q3 FY26 Revenue: INR 166.32 crores vs INR 146.55 crores (Q3 FY25) | 2026-02-23 |
| Quarterly results · Q3 FY26 LINCOLN PHARMACEUTICALS LIMITED – DOCUMENT SUMMARY --- HEADLINE NUMBERS • Q3 FY26 Net Profit: Rs. 28.60 crore, up 37.70% Y-o-Y (vs Rs. 20.77 crore | 2026-02-12 |
| Quarterly results · Q2 FY26 LINCOLN PHARMACEUTICALS LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 FY26 Net Profit: Rs. 20.01 crore (down 24.06% Y-o-Y from Rs. 26.35 crore i | 2025-11-13 |
| Annual report FY2025 LINCOLN PHARMACEUTICALS LIMITED – ANNUAL REPORT FY25 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹623.23 crore • Total Income: ₹645.71 crore | 2025-09-06 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.80 / share ex-date Sep 11, 2026 | 2026-09-11 |
| Dividend | ₹1.80 / share ex-date Sep 12, 2025 | 2025-09-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lincoln Pharmaceuticals Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.